Review

Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease

Ayokanmi Ore 1,2,* and Oluseyi Adeboye Akinloye 1

1 Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria; oaaakin@yahoo.com
2 Biochemistry Division, Department of Chemical Sciences, Faculty of Natural Sciences, Ajayi Crowther University, Oyo, Nigeria
* Correspondence: oreayokanmi@gmail.com or ayokanmi.ore@pg.funaab.edu.ng; Tel.: +234-806-165-6814

Received: 5 January 2019; Accepted: 18 January 2019; Published: 24 January 2019

Abstract: Non-alcoholic fatty liver disease (NAFLD) is a term that covers a range of hepatic disorders involving fat deposits in the liver. NAFLD begins with simple steatosis and progresses into non-alcoholic steatohepatitis (NASH) characterised by inflammation, fibrosis, apoptosis, oxidative stress, lipid peroxidation, mitochondrial dysfunction and release of adipokines and pro-inflammatory cytokines. Oxidative stress and antioxidants are known to play a vital role in the pathogenesis and severity of NAFLD/NASH. A number of oxidative stress and antioxidant markers are employed in the assessment of the pathological state and progression of the disease. In this article, we review several biomarkers of oxidative stress and antioxidants that have been measured at clinical and experimental levels. Also included is a comprehensive description of oxidative stress, sources and contribution to the pathogenesis of NAFLD/NASH.

Keywords: liver; NAFLD; NASH; biomarkers; reactive species; oxidative stress; lipid peroxidation; antioxidants

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is a range of hepatic disorders associated with fatty deposits in the liver, which occur in the absence of alcohol consumption or alcohol abuse [1]. NAFLD begins with an initial stage of fatty liver also known as hepatic steatosis (excessive fat loading in the hepatocytes). The progression from steatosis into cirrhosis of the liver due to inflammation and fibrosis results in irreversible damage to the liver [2]. This condition is called non-alcoholic steatohepatitis (NASH)—a term first introduced by Ludwig et al. [3] in clinical subjects with no history of alcohol consumption or abuse.

NAFLD is one of the most common chronic hepatic pathology. It has a worldwide distribution with an estimated prevalence of 25% for NAFLD and about 5% for NASH [4]. The highest prevalence of NAFLD is observed in Western countries (17% to 46%) where it is the most common chronic liver disease (CLD) in adults with a high prevalence of NASH in the United States (16%). The World Gastroenterology Organisation suggests that the prevalence of NAFLD had doubled over the last 20 years. NAFLD and NASH are closely associated with diabetes and obesity, and together are considered one of the major causes of liver disease in Western countries [5].

The pathophysiology of NASH was originally explained by the “two-hit” hypothesis [6]. In this hypothesis, the first hit is responsible for producing steatosis (fat accumulation in liver), and the second hit is from oxidative stress causing lipid peroxidation. The pathogenesis and progression of NAFLD is complex, and was not completely explained by the “two hit” hypothesis. Currently, NASH is described...
by the “multiple hit” hypothesis [7]. In this hypothesis, metabolic syndrome plays a major role due to insulin resistance and the inflammatory process mediated by interaction of different proteins and immune system. The components of the multiple “hits” are yet to be fully defined and they may vary in different patients. However, from available information, the “first hit” is caused by metabolic syndrome and insulin resistance, increased fat loading in hepatocytes leading to steatosis and liver injury. The accumulation of fat in the liver occur as a result of imbalance between the rate of influx and removal of triglycerides—a mechanism thought to protect hepatocytes from the lipotoxicity that may result from excessive influx of free fatty acids (FFAs) [8]. Most of the FFAs stored as triglycerides originate from increased lipolysis in peripheral tissues as a result of adipose tissue insulin resistance (IR), attended by increased lipogenesis due to hyperinsulinemia and diet fat. The subsequent “hits” are responsible for the inflammation, fibrosis, apoptosis, oxidative stress (OS), and hepatic lipid peroxidation, mitochondrial dysfunction, release of adipokines and pro-inflammatory cytokines [7] (Figure 1). Major histopathological features of NASH are steatosis, hepatocellular ballooning, lobular inflammation and in some cases, fibrosis [7,8] and may progress into cirrhosis if left unchecked.

![Figure 1. Pathophysiology of NASH and the multi-hit hypothesis.](image)

An understanding of the mechanism of OS, its regulation as well as its role in NAFLD is vital. This will provide researchers in the area of NAFLD/NASH with the best choice of OS/antioxidant (AO) biomarkers useful in pre-clinical investigations as well as in clinical diagnosis of NAFLD. Development of potent drugs in the treatment of NAFLD will also take the AO action required to counteract the OS associated with NAFLD into consideration. In this article, we review the role of oxidative stress in NAFLD and several AO and OS biomarkers that have been measured in pre-clinical and clinical evaluations.

2. Oxidative Stress

OS refers to an imbalance between the production of reactive species (RS) and AO defenses [9]. A more encompassing definition describes it as “an imbalance between oxidants and AOs in favour of the oxidants, leading to a disruption of redox signalling and control and/or molecular damage” [9,10]. RS (the oxidants) are chemically reactive species containing oxygen (reactive oxygen species, ROS), or nitrogen (reactive nitrogen species, RNS), etc. (Table 1). ROS (which are the most extensively studied RS) are oxygen-containing molecules that exhibit higher chemical reactivity than oxygen (O2). Some ROS are free radicals (e.g., hydroxyl radical, superoxide radical, peroxyl radical etc.), others are non-radicals (e.g., hydrogen peroxide, hypochlorous acid, lipid peroxides etc.). RNS that
are free radicals include nitric oxide, nitrogen dioxide etc., and those that are non-radicals include dinitrogen trioxide, peroxinitrite, etc. (Table 1). OS has been classified according to severity as “eustress” (physiological oxidative stress) and “distress” (toxic oxidative burden which damages biomolecules) [10,11]. In other words, low exposure to OS is useful for redox signalling, whereas high exposure results in disruption of redox signalling and causes damage to important biomolecules.

### Table 1. Major ROS and RNS of physiological importance.

| Major ROS | Sources |
|-----------|---------|
| **Free Radicals** | | |
| Hydroxyl radical (OH•) | Decomposition of ONOO− or HOCl |
| Superoxide radical (O2•−) | Electron transport systems, and one-electron reduction of O2 by respiratory burst via the action of membrane bound NADPH oxidase |
| Peroxyl radical (ROO•) | Produced in the Fenton reaction |
| **Non-Radicals** | | |
| Hydrogen peroxide (H2O2) | Activated macrophages during inflammation |
| Hypochlorous acid (HClO) | Combined activities of NADPH oxidase and myeloperoxidase (MPO) in phagocytes |
| Lipid peroxides (ROOH) | Formed from oxidation of polyunsaturated fatty acid via lipid-peroxyl radical reaction |
| **Major RNS** | | |
| **Free Radicals** | | |
| Nitric oxide (NO•) | Nitric Oxide Synthase (NOS) |
| Nitrogen dioxide (N2O5•) | Activated neutrophils |
| Dinitrogen trioxide (N2O3) | Produced in pathological conditions where (inducible nitric oxide (iNOS) is upregulated |
| Peroxinitrite (ONOO•) | Produced in pathological conditions where iNOS is upregulated |
| Nitrite (NO2−) | Oxidation product from NO, formed during NOS activation in inflammatory diseases |
| Nitryl ion (NO2+•) | Activated neutrophils |
| **Non-radicals** | | |

### 3. Oxidative Damage to Macromolecules

OS is associated with many diseases, especially those with an inflammatory mechanism [12]. OS is known in several hepatic diseases with high levels of ROS and RNS, which is an important description of the severity and progression of the disease [13,14]. ROS is constantly generated in the cell due to partial reduction of O2 or as a result of transfer of energy to O2. ROS can attack vital cell components like polyunsaturated fatty acids, proteins, and nucleic acids, and also carbohydrates in a few cases [15–17]. They can disrupt membrane properties like fluidity and ion transport, cause loss of enzyme activity, disruption of the protein synthesis mechanism and induction of DNA damage, ultimately leading to cell death. Damage resulting from OS is often called “oxidative damage”.

Oxidative damage to macromolecules (lipids, proteins, DNA etc.) results in formation of oxidative damage products (Table 2), which are often measured as biomarkers of OS [18–21]. Some of the most important oxidative damage products of lipids that are frequently measured includes malondialdehyde, lipid peroxides, 8-isoprostane, and 4-hydroxy-2-nonenal (4-HNE). Oxidation of protein can result in protein cross linkage, formation of protein carbonyls, and modification of amino acid. Important products of oxidative modification of amino acids that are frequently measured include 3-nitrotyrosine (a product of ROS-mediated nitration of tyrosine), 2-oxohistidine and hydroxyproline (Table 2). DNA/RNA oxidation can cause single or double strand fragmentation or modification of bases or sugar. 8-Hydroxy-2′-deoxyguanosine (8-OH-dG) and 8-hydroxyguanine (8-OH-G) are the most commonly measured DNA/RNA damage products.
Table 2. Some important oxidative damage products.

| Macromolecule | Oxidative Damage          | Damage Products                                                                 |
|---------------|---------------------------|---------------------------------------------------------------------------------|
| Lipids        | Lipid oxidation/peroxidation | Malondialdehyde (MDA) Lipid peroxide, (lipid endoperoxides and lipid hydroperoxides) 8-Isoprostane 4-hydroxy-2-nonenal (4-HNE) |
| Proteins      | Protein Oxidation, protein cross linkage, Oxidative modification of amino acids | Protein carbonyl compounds, 3-Nitrotyrosine (product of ROS-mediated nitration of tyrosine), 2-oxohistidine, hydroxyproline etc. |
| DNA           | RNA/DNA fragmentation (single and double-strand breaks) Modification of base, sugar | 8-hydroxy-2′-deoxyguanosine (8-OH-dG), 8-hydroxyguanine (8-OH-G) |

4. Regulation of OS

There are several mechanisms for the cellular regulation of OS, which are extremely important to the cell homeostasis. This is achieved through the antioxidant system, which can control the formation of ROS or RNS and also repair oxidative damage to cells. An antioxidant is any substance that can inhibit the oxidation of the cell components such as DNA, proteins and lipids. Several levels of antioxidative defense mechanism are used to prevent oxidative damage [22,23]. The antioxidants can be derived from the diet or endogenously.

Endogenously derived antioxidants are classified as enzymic or non-enzymic antioxidants (Table 3). Enzymic antioxidants of endogenous origin include superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase, etc. SOD catalyse the dismutation of superoxide radical to hydrogen peroxide. The hydrogen peroxide formed in this process and other processes is detoxified by the action of catalase or glutathione peroxidase utilising the power of reduced glutathione (GSH). The latter becomes oxidised (to GSSG) and can be reduced back to GSH through the action of glutathione reductase. Some of the most physiologically vital non-enzymic antioxidants include ascorbate, glutathione, α-tocopherol (vitamin E), Ubiquinone, Thioredoxin (TRX), Bilirubin etc. These antioxidant substances are effective in the detoxification of free radicals and reactive species in the cell (Table 3).

Table 3. Physiologically important antioxidants and their functions.

| Antioxidant Type  | Antioxidant Name | Functions                                                                 |
|-------------------|------------------|--------------------------------------------------------------------------|
| Enzymic antioxidants | Superoxide dismutase (SOD) Catalase (CAT) Glutathione peroxidase (GPx) Glutathione reductase (GR) | Converts $O_2^−$ to $H_2O_2$ and $O_3$ Converts $H_2O_2$ to $2H_2O$ and $O_2$ Detoxifies $H_2O_2$ and Lipid peroxides using reduced glutathione (GSH) producing the oxidised form of glutathione (GSSG) Reduces GSSG to GSH |
| Non-enzymic antioxidants | Ascorbic Acid (AA) Reduced Glutathione (GSH) α-Tocopherol Ubiquinone Thioredoxin (TRX) Bilirubin | Detoxifies Superoxide radical, Hydroxyl radical, and $H_2O_2$ Neutralizes Superoxide radical, Hydroxyl radical, and $H_2O_2$; co-substrate for glutathione peroxidase Detoxifies $H_2O_2$; protects against membrane lipid peroxidation (LPO) General thiol redox control of protein activity via reversible disulfide formation Effective in quenching/scavenging secondary oxidants produced during OS |

5. Sources and Role of OS in NAFLD/NASH

The sources of OS, as well as its role in NASH has been extensively reviewed by Koek et al. [24] and Tariq et al. [25]. OS results from excessive generation of reactive species (RS) or depletion of physiological redox homeostasis. RS (ROS or RNS) from the inflammatory response, the mitochondria, endoplasmic reticulum and peroxisomes also contribute to OS associated with NAFLD/NASH. Their sources and role in NAFLD/NASH are summarized in Table 4.
Table 4. Sources of oxidative stress in NAFLD/NASH.

| Source                                   | Contribution to OS in NAFLD/NASH                                                                 | References |
|------------------------------------------|------------------------------------------------------------------------------------------------|------------|
| Mitochondrial metabolism (β-oxidation)   | Production of ROS as a result of electron leakage during mitochondrial β-oxidation             | [26–30]   |
| Peroxisomal β-oxidation                  | Generation of H$_2$O$_2$ during peroxisomal β-oxidation which is converted into hydroxyl radical contributing to OS | [31]      |
| Mitochondrial electron transport chain   | Inhibition of electron transport chain by TNF-α and lipid peroxidation products                | [32,33]   |
| Microsomal Cytochrome P450 enzymes       | ROS generation due to Increase in activity of cytochrome P450E1 (CYP2E1) involved in lipoxygenation of longchain fatty acids | [34–37]   |
| Endoplasmic reticulum (ER) stress        | Endoplasmic reticulum stress response, promotes OS via increased expression of CHOP (also called DDIT –DNA Damage Inducible Transcript-3 protein) | [38]      |
| Xanthine Oxidase (XO)                    | Increase in XO activity generates superoxide anions, due to induction by 4-HNE (a product of lipid peroxidation) | [39,40]   |
| Inflammatory Response                    | Abnormal inflammatory response mediated by gut microflora resulting in increase in pro-oxidants | [41–43]   |

OS has been reported to play a significant role in the pathophysiological mechanism of NAFLD and NASH [44,45]. Studies conducted in humans and animal models showed a strong association between the level of OS and the severity of NASH [26,46]. Although clinical and experimental studies have reported higher levels of lipid peroxidation in NASH patients, the levels of circulating antioxidants have been less reported.

6. Antioxidant and OS Markers Measured in NAFLD/NASH

Several biomarkers of oxidative stress and antioxidants have been detected in clinical and experimental models of NAFLD and NASH. Most of these are assayed predominantly in the liver, serum, plasma, and in a few cases, in whole blood samples. Major assay procedures for the detection of these markers include colorimetry, ELISA, and immunohistochemistry.

6.1. Antioxidant Markers Measured in Clinical NAFLD/NASH

At the clinical level, a number of antioxidants have been determined in the evaluation of NAFLD/NASH. They include the enzymic antioxidants: CAT, SOD, GPx, GR [47–54], and non-enzymic antioxidants: ascorbic Acid, GSH, α-Tocopherol, Ubiquinone, Thioredoxin (TRX) and Bilirubin [48–58] (Table 5). In general, the activities/concentrations of these antioxidants tend to decrease in NAFLD/NASH patients with a few exceptions where they increased. These variations appear to be sample dependent: for instance, those determined in the liver samples of patient generally showed a decrease in their activities/levels in all the data reviewed. However, there are variations with respect to other samples such as blood, plasma and serum, where antioxidant levels tend to increase in most cases of NAFLD and NASH.
Table 5. Antioxidant markers measured in clinical NAFLD/NASH.

| Antioxidant Marker | Sample  | Level/Activity/Expression in Sample | Clinical Case | Reference(s) |
|--------------------|---------|-------------------------------------|---------------|--------------|
| SOD                | Serum   | Decreased, Increased (nsc)          | NASH          | [47–49]      |
|                    | Serum/Liver | Decreased                        | NAFLD         | [51]         |
|                    | Plasma   | Decreased                          | NAFLD         | [51]         |
|                    | Blood    | Increased                          | NAFLD         | [52]         |
|                    | Liver    | Decreased                          | NAFLD         | [53]         |
|                    | Blood    | Increased                          | NAFLD         | [54]         |
| CAT                | Serum   | Decreased, Increased (nsc)          | NASH          | [47,48]      |
|                    | Plasma   | Decreased                          | NAFLD         | [51]         |
|                    | Blood    | Increased                          | NAFLD         | [52]         |
|                    | Liver    | Decreased                          | NAFLD         | [53]         |
|                    | Blood    | Decreased                          | NAFLD         | [54]         |
| GPx                | Serum   | Decreased                          | NASH          | [48,49]      |
|                    | Blood    | Increased                          | NAFLD         | [54]         |
|                    | Liver    | Decreased                          | NAFLD         | [55]         |
| GR                 | Serum   | Increased                          | NASH          | [49]         |
|                    | Blood    | Increased                          | NAFLD         | [54]         |
|                    | Liver    | Increased                          | NAFLD         | [55]         |
| Ascorbic Acid      | Serum   | nsc                                | NASH          | [48]         |
|                    | Serum    | Decreased                          | NAFLD         | [51]         |
| GSH                | Serum   | Increased                          | NASH          | [49]         |
|                    | Blood    | Increased                          | NAFLD         | [52]         |
|                    | Liver    | Decreased                          | NAFLD         | [53]         |
|                    | Blood    | Decreased                          | NAFLD         | [54]         |
| α-Tocopherol       | Serum   | Increased                          | NASH          | [48]         |
|                    | Serum    | Decreased                          | NAFLD         | [51]         |
| Ubiquinone         | Serum   | Decreased                          | NAFLD         | [51]         |
| Thioredoxin (TRX)  | Serum   | Increased                          | NAFLD         | [55]         |
| Bilirubin          | Serum   | Decreased                          | NASH          | [56,57]      |
|                    | Serum    | Decreased                          | NAFLD         | [58]         |

nsc: no significant change.

6.2. Oxidative Stress Markers Measured in Clinical NAFLD/NASH

Oxidative stress biomarkers that have been determined in clinical models of NAFLD include nitric oxide (NO), lipid damage products (lipid peroxides, TBARS (MDA), Hydroperoxides, 8-Isoprostane, 4-HNE), protein oxidation products (protein carbonyl, Nitrotyrosine), DNA oxidation product (8-OH-dG) and CYP2E1 (Table 6). The concentrations/activities of these biomarkers increase generally in all the clinical data reviewed, except where the increase is not significant [52] (Table 6). The most frequently reported OS markers include the NO, MDA, 8-OH-dG and CYP2E1.

Table 6. Oxidative stress markers measured in clinical NAFLD/NASH.

| OS Marker          | Sample  | Level/Activity/Expression in Sample | Clinical Case | Reference(s) |
|--------------------|---------|-------------------------------------|---------------|--------------|
| Lipid peroxides    | Plasma  | Increased                           | NASH          | [59]         |
| NO*                | Serum   | Increased                           | NASH          | [47,49]      |
|                    | Serum   | Increased                           | NAFLD         | [50,60]      |
|                    | Blood   | Increased                           | NAFLD         | [52]         |
| TBARS/MDA          | Serum   | Increased                           | NAFLD         | [47]         |
|                    | Serum   | Increased                           | NAFLD         | [49,51,61]   |
|                    | Serum   | Increased                           | NAFLD         | [50]         |
|                    | Blood   | Increased                           | NAFLD         | [54]         |
| Hydroperoxides     | liver   | Increased                           | NASH          | [62]         |
| 8-Isoprostane      | Plasma  | Increased                           | NASH          | [48]         |
| 4-HNE              | Liver   | Increased                           | NASH          | [63]         |
| Protein carbonyl   | Liver   | Increased                           | NAFLD         | [53]         |
| Nitrotyrosine      | Blood   | nsc                                | NAFLD         | [52]         |
| 8-OH-dG            | Liver   | Increased                           | NASH          | [63,64]      |
|                    | Liver   | Increased                           | NAFLD         | [65]         |
| CYP2E1             | Liver   | Increased                           | NASH          | [34,35]      |
|                    | Liver   | nsc                                | Steatosis/NASH| [66]         |
|                    | Liver   | Increased                           | NAFLD         | [53]         |

nsc: no significant change.
6.3. Antioxidant Markers Measured in Experimental Models of NAFLD/NASH

Extensive data on antioxidants used to assess NAFLD/NASH in experimental models have been reviewed. They mainly cover the enzymic antioxidants: SOD, CAT, GPx, GR and the non-enzymic antioxidant—GSH in about five rodent models. In nearly all the experimental data reviewed, these antioxidants were measured in the liver and their activities decreased generally in most of the models (mainly NASH), except in a few cases as shown in Table 7.

Table 7. Antioxidant markers measured in experimental NAFLD/NASH.

| Antioxidant Marker | Sample | Level/Activity/Expression in Sample | Experimental Model | Experimental Specie | Reference(s) |
|--------------------|--------|-------------------------------------|--------------------|---------------------|--------------|
| SOD                | Liver  | Decreased                           | NASH (MCD)         | Wistar Rats         | [67]         |
|                    | Liver  | Increased                           | NASH (MCD)         | C57BL/6 Mice        | [68]         |
|                    | Liver  | Increased                           | NASH (MCD)         | C57BL/6 mice        | [68]         |
|                    | Liver  | Decreased                           | NASH (MCD)         | N-Mary rats         | [71]         |
|                    | Liver  | Decreased                           | NAFLD (HFD)        | Mice                | [72]         |
|                    | Liver  | Decreased                           | NASH (HF)          | Kunming mice        | [73]         |
|                    | Liver  | Increased                           | NAFLD (HFD)        | Rat                 | [74]         |
| CAT                | Liver  | Decreased                           | NASH (MCD)         | Wistar Rats         | [67]         |
|                    | Liver  | Decreased                           | NASH (MCD)         | C57BL/6 Mice        | [68]         |
|                    | Liver  | Decreased                           | NASH (MCD)         | C57BL/6 mice        | [68]         |
|                    | Liver  | Decreased                           | NASH (HCD)         | Wistar Rats         | [75]         |
|                    | Liver  | Decreased                           | NAFLD (HFD)        | Sprague-Dawley rats | [74]         |
| GPx                | Liver  | Decreased                           | NASH (MCD)         | Wistar Rats         | [67]         |
|                    | Liver  | Increase                            | NASH (MCD)         | N-Mary rats         | [71]         |
|                    | Liver  | Decreased                           | NAFLD (HFD)        | Mice                | [72]         |
|                    | Liver  | Decreased                           | NASH (HF)          | Kunming mice        | [73]         |
|                    | Liver  | nsc                                 | NAFLD (HFD)        | Sprague-Dawley rats | [74]         |
| GR                 | Liver  | Decreased                           | NASH (MCD)         | N-Mary rats         | [71]         |
| GSH                | Liver  | Decreased                           | NASH (MCD)         | Wistar Rat          | [67]         |
|                    | Liver  | Decreased                           | NASH (MCD)         | N-Mary rats         | [71]         |
|                    | Liver  | Decreased                           | NAFLD (HFD)        | Wistar Rats         | [76]         |
|                    | Liver  | Decreased                           | NAFLD (HCD)        | Wistar Rats         | [75]         |
|                    | Liver/RBC| Increased                         | NASH (HF-MCD)      | Sprague-Dawley rats | [77]         |
|                    | Liver  | Decreased                           | NASH (MCD)         | Mice                | [78]         |

MCD: Methionine/Choline Deficient Diet; HF: High fructose Diet; HFD: High Fat Diet; HCD: High Cholesterol diet; HF-MCD: High fat- methionine choline deficient diet; nsc: no significant change.

6.4. Oxidative Stress Markers Measured in Experimental Models of NAFLD/NASH

Oxidative stress biomarkers measured at experimental level of NAFLD/NASH include the reactive species (H$_2$O$_2$, nitrite/nitrate), lipid oxidation products (MDA, Lipid peroxide, 8-Isoprostanes, 4-HNE), protein damage products (Protein carbonyl, Dityrosine, Hydroxyproline, Nitrotyrosine), DNA damage product (8-OH-dG), and oxidative enzymes (CYP2E1, NADPH Oxidase, Xanthine Oxidase), as summarized in Table 8.

The levels or activities of these biomarkers are found to consistently increase in all of the experimental models, except where the increases were not significant. In all the experimental models, MDA is the most measured oxidative stress biomarker as presented in Table 8. Next to MDA is 4-HNE (another product of lipid oxidation), 8-OH-dG and CYP2E1. Others like H$_2$O$_2$, nitrite/nitrate, lipid peroxide, 8-Isoprostanes, Protein carbonyl, Dityrosine, Hydroxyproline, Nitrotyrosine), NADPH Oxidase and Xanthine Oxidase are not frequently measured. However, their levels/activities increase in a similar pattern to MDA, 8-OH-dG, 4-HNE, CYP2E1.
Table 8. Oxidative stress markers measured in experimental NAFLD/NASH.

| OS Marker | Sample Level/Activity/Expression in Sample | Experimental Model | Experimental Specie | Reference(s) |
|-----------|------------------------------------------|--------------------|--------------------|--------------|
| H2O2      | Liver Increased                           | NASH (MCD)         | C57BL/6J-mtFVB/N mice | [79]         |
| Nitrite/nitrate | Liver Nsc | NAFLD (HFD) | Wistar Rats | [76] |
| TBARS (MDA) | Liver Increased | NASH | C57BL/6 J mice | [80] |
|          | Liver Increased | NASH (MCD) | C57BL/6 mice | [70] |
|          | Liver Increased | Steatosis/NASH (HFD) | Albino rats | [81] |
|          | Liver Increased | NASH (MCD) | C57BL/6 mice | [69] |
|          | Liver Increased | Steatosis (HFD/HSD) | Wistar rats | [82] |
|          | Liver Increased | HF/HGD | Wistar rats | [83] |
|          | Liver Increased | NAFLD (HFD) | C57BL/6J-mtFVB/N mice | [84] |
|          | Liver Increased | NAFLD (HFD) | C57BL/6 mice | [85] |
|          | Liver Increased | NASH (MCD) | C57BL/6 mice | [54,91,92] |
|          | Liver Increased | NASH (FD/NASH) | C57BL/6J-mtFVB/N mice | [79] |
| Lipid peroxide | Liver Increased | NASH (MCD) | Wistar Rats | [67] |
| 8-Isoprostanes | Liver Increased | NASH (HFD) | Sprague-Dawley rats | [77] |
| 4-HNE      | Liver Increased | NASH (HFD) | Sprague-Dawley Rat | [78] |
|          | Liver Increased | NASH (MCD) | Wistar Rats | [67] |
|          | Liver Increased | NASH (FD/CDHF diet) | Wistar Rats | [87] |
|          | Liver Increased | NASH (MCD) | N-Mary rats | [71] |
|          | Liver Increased | NASH (MCD) | C57BL/6J mice | [69] |
|          | Liver Increased | NASH (HF) | Kunming mice | [73] |
|          | Liver Increased | NASH (MCD) | C57BL/6J-mtFVB/N mice | [79] |
| Protein carbonyl | Liver Increased | NASH (MCD) | N-Mary rats | [83] |
| Nitrotyrosine | Liver Increased | NAFLD | CYP2E1 transgenic (Tg) mice | [93] |
| Dityrosine  | Liver Increased | NAFLD (HFD) | C57BL/6 mice | [84] |
| Hydroxyproline | Liver Increased | NAFLD/NASH (CDAA diet) | Wistar Rats | [86] |
|          | Liver Increased | NAFLD (MCD/WD) | C57BL6 mice | [54] |
| 8-OH-dG    | Liver Increased | NASH (MCD) | Wistar Rats | [89] |
|          | Liver Decreased | NASH (HF-MCD) | Sprague-Dawley rats | [79] |
|          | Liver Increased | NAFLD (HFD) | C57BL/6J mice | [86] |
| CYP2E1     | Liver Increased | NASH (MCD) | CYP2E1 transgenic (Tg) mice | [92,93] |
|          | Liver Increased | NASH (HFD) | Sprague-Dawley Rat | [88] |
|          | Liver Increased | NASH (HFD) | Sprague-Dawley Rat | [94] |
|          | Liver Increased | Steatosis (HFD/HSD) | Wistar rats | [82] |
|          | Liver Increased | NASH (CDHF diet) | Wistar rats | [86] |
| NADPH Oxidase | Liver Increased | NASH | ob/ob mice | [89] |
| Xanthine Oxidase | Liver Increased | NAFLD (HFD) | Sprague-Dawley rats | [74] |

MCD: Methionine/Choline Deficient Diet; HF: High fructose Diet; HFD: High Fat Diet; HCD: High Cholesterol diet; HSD: High Sucrose diet; CDAA: Choline Deficient L-Amino Acid-defined; CDHF: Choline Deficient High Fat diet; HFMCD: High fat methionine choline deficient diet; HF-HSD: High fat-high sucrose diet; WD: Western diet; HF/HGD: High-Fructose/High-Glucose Diet; nsc: no significant change.

7. Conclusions

Oxidative stress plays an important role in the pathophysiology of NAFLD/NASH. Several markers of oxidative stress and antioxidants have been shown to be very useful in assessing the redox state in NAFLD/NASH. Among the oxidative stress biomarkers reviewed, TBARS, MDA, CYP2E1 and 4-HNE are unique; they are represented in both clinical and experimental measurements and they consistently increase. Antioxidants of interest in clinical and pre-clinical assessment of NAFLD/NASH include GSH, SOD, CAT, and GPx, which appear to be most reliably detected in liver samples.
Author Contributions: Writing-Original Draft Preparation, A.O.; Writing-Review & Editing, O.A.A.

Funding: This review received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Angulo, P. Non-alcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221–1231. [CrossRef] [PubMed]
2. Manne, V.; Handa, P.; Kowdley, K.V. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin. Liver Dis. 2018, 22, 23–37. [CrossRef] [PubMed]
3. Ludwig, J.; Viggiano, T.R.; McGill, D.B.; Oh, B.J. Non-alcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55, 434–438. [PubMed]
4. Kim, W.R.; Lake, J.R.; Smith, J.M.; Skeans, M.A.; Schladt, D.P.; Edwards, E.B.; Harper, A.M.; Wainright, J.L.; Snyder, J.J.; Israni, A.K.; et al. OPTN/SRTR 2015 Annual Data Report: Liver. Am. J. Transplant. 2017, 17, 174–251. [CrossRef] [PubMed]
5. European Association for the Study of Liver (EASL). Background Media Information: Fast facts about liver disease. Int. Liver Congr. 2016, 1–5.
6. Day, C.P.; James, O. Steatohepatitis: A tale of two ‘hits’? Gastroenterol. 1998, 114, 842–845. [CrossRef]
7. Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of nonalcoholic fatty liver disease (NAFLD). Metabolism 2016, 65, 1038–1048. [CrossRef]
8. Dongiovanni, P.; Anstee, Q.M.; Valenti, L. Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. Curr. Pharm. Des. 2013, 19, 5219–5238. [CrossRef]
9. Sies, H.; Berndt, C.; Jones, D.C. Oxidative stress. Annu. Rev. Biochem. 2017, 86, 715–748. [CrossRef]
10. Sies, H. On the history of oxidative stress: Concept and some aspects of current development. Curr. Opin. Toxicol. 2018, 7, 122–126. [CrossRef]
11. Lushchak, V.I. Free radicals, reactive oxygen species, oxidative stress and its classification. Chem. Biol. Interact. 2014, 224C, 164–175. [CrossRef] [PubMed]
12. Li, S.; Hong, M.; Tan, H.; Wang, N.; Feng, Y. Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid. Med. Cell. Longev. 2016, 1, 1–21. [CrossRef] [PubMed]
13. Li, S.; Tan, H.; Wang, N.; Zhang, Z.; Lao, L.; Wong, C.; Feng, Y. The Role of Oxidative Stress and Antioxidants in Liver Diseases. Int. J. Mol. Sci. 2015, 16, 26087–26124. [CrossRef] [PubMed]
14. Cicho´z-Lach, H.; Michalak, A. Oxidative stress as a crucial factor in liver diseases. World J. Gastroenterol. 2014, 20, 8082–8091. [CrossRef] [PubMed]
15. Muriel, P. Role of free radicals in liver diseases. Hepatol. Int. 2009, 3, 526–536. [CrossRef] [PubMed]
16. Barzilai, A.; Yamamoto, K. DNA damage responses to oxidative stress. DNA Repair 2004, 3, 1109–1115. [CrossRef] [PubMed]
17. d’Ischia, M.; Manini, P.; Napolitano, A. Oxidative Damage to Carbohydrates and Amino Acids. In Oxidative Stress, Disease and Cancer; Word Scientific: Singapore, 2006; pp. 333–356. [CrossRef]
18. Hassan, H.A.; El-Aal, M.A. Lipid Peroxidation End-Products as a Key of Oxidative Stress: Effect of Antioxidant on Their Production and Transfer of Free Radicals. In Lipid Peroxidation; Catala, A., Ed.; InTech: Rijeka, Croatia, 2012; pp. 63–88. [CrossRef]
19. Sitte, N. Oxidative Damage to Proteins. In Aging at the Molecular Level; Zglinicki, T., Ed.; Springer-Science: Newcastle, UK, 2003. [CrossRef]
20. Gackowski, D.; Speina, E.; Zielinska, M.; Kowalewski, J.; Rozalski, R.; Siomek, A.; Paciorek, T.; Tudek, B.; Olinski, R. Products of oxidative DNA damage and repair as possible biomarkers of susceptibility to lung cancer. Cancer Res. 2003, 15, 4899–4902.
21. Nishida, N.; Arizumi, T.; Takita, M.; Kitai, S.; Yada, N.; Hagiwara, S.; Inoue, T.; Minami, Y.; Ueshima, K.; Sakurai, T.; et al. Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis. Dig. Dis. 2013, 31, 459–466. [CrossRef]
22. Simioni, C.; Zauli, G.; Martelli, A.M.; Vitale, M.; Sacchetti, G.; Gonelli, A.; Neri, L.M. Oxidative stress: Role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget 2018, 9, 17181–17198. [CrossRef]
23. Valko, M.; Leibfritz, D.; Moncola, J.; Cronin, M.T.D.; Mazura, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44–84. [CrossRef]
43. Dostert, K.; Dorn, C.; Weiss, T.; Gabele, E.; Hellerbrand, C. Enhanced TLR4 expression in steatotic hepatocytes. *Clin. Chim. Acta* 2011, 412, 1297–1305. [CrossRef] [PubMed]

25. Tariq, Z.; Green, C.J.; Hodson, L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? *Liver Int.* 2014, 34, 180–190. [CrossRef] [PubMed]

36. Matsunami, T.; Sato, Y.; Ariga, S.; Sato, T.; Kashimura, H.; Hasegawa, Y.; Yukawa, M. Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. *Hepatology* 2003, 37, 544–550. [CrossRef] [PubMed]

32. Pessayre, D.; Mansouri, A.; Fromenty, B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2002, 282, 193–199. [CrossRef]

27. Vendemiale, G.; Grattagliano, I.; Caraceni, P.; Caraccio, G.; Domenicali, M.; Dall’Agata, M.; Trevisani, F.; Guerrieri, F.; Bernardi, M.; Altomare, E. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status. *Hepatology* 2001, 33, 808–815. [CrossRef] [PubMed]

38. Yang, L.; Jhaveri, R.; Huang, J. Endoplasmic reticulum stress, hepatocyte CD1 and NKT cell abnormalities in non-alcoholic fatty liver disease. *Int. J. Clin. Exp. Pathol.* 2010, 4, 472–481. [CrossRef] [PubMed]

37. Leclercq, A.; Farrell, G.C.; Field, J.; Bell, D.R.; Gonzalez, F.J.; Robertson, G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. *J. Clin. Invest.* 2000, 105, 1067–1075. [CrossRef] [PubMed]

35. Chalasani, N.; Gorski, J.C.; Asghar, M.S.; Asghar, A.; Foresman, B.; Hall, S.D.; Crabb, D.W. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. *Hepatology* 2003, 37, 44–50. [CrossRef] [PubMed]

40. Baskol, G.; Baskol, M.; Kocer, D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. *Clin. Biochem.* 2007, 40, 776–780. [CrossRef]

24. Koek, G.H.; Liedorp, P.R.; Bast, A. The role of oxidative stress in non-alcoholic steatohepatitis. *Clin. Chim. Acta* 2011, 412, 1297–1305. [CrossRef] [PubMed]

26. Serviddio, G.; Sastre, J.; Bellanti, F.; Viña, J.; Vendemiale, G.; Altomare, E. Mitochondrial involvement in non-alcoholic steatohepatitis. *Mol. Asp. Med.* 2008, 29, 22–35. [CrossRef] [PubMed]

29. Haque, M.; Sanya, A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2002, 282, 193–199. [CrossRef]

31. Gonzalez, F.J.; Peters, J.M.; Cattley, R.C. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. *J. Natl. Cancer Inst.* 1998, 90, 1702–1709. [CrossRef] [PubMed]

1067–1075. [CrossRef] [PubMed]
44. Ucar, F.; Sezer, S.; Erdogan, S.; Akyol, S.; Armutcu, F.; Akyol, O. The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis. *Redox Rep.* 2013, 18, 127–133. [CrossRef] [PubMed]

45. Gambino, R.; Musso, G.; Cassader, M. Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. *Antioxid. Redox Signal.* 2011, 15, 1325–1365. [CrossRef] [PubMed]

46. Rolo, A.P.; Teodoro, J.S.; Palmeira, C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. *Free Radic. Biol. Med.* 2012, 52, 59–69. [CrossRef] [PubMed]

47. Stiuso, P.; Scognamiglio, I.; Murolo, M.; Ferranti, P.; De Simone, C.; Rizzo, M.R.; Tuccillo, C.; Caraglia, M.; Loguercio, C.; Federico, A. Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study. *Oxidat. Med. Cell. Longev.* 2014, 2014, 1–8. [CrossRef] [PubMed]

48. Leghi, G.E.; Domenici, F.A.; Vannucchi, H. Influence of oxidative stress and obesity in patients with nonalcoholic steatohepatitis. *ARQ Gastroenterol.* 2015, 52, 228–233. [CrossRef] [PubMed]

49. Koruk, M.; Taysi, S.; Savas, M.C.; Yilmaz, O.; Akcay, F.; Karakok, M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. *Ann. Clin. Lab. Sci.* 2004, 34, 57–62. [PubMed]

50. Köroğlu, E.; Canbakan, B.; Atay, K.; Hatemi, I.; Tuncer, M.; Dobrucalı, A.; Sonsuz, A.; Gültepe, I.; Şentürk, H. Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease. *Turk. J. Gastroenterol.* 2016, 27, 361–366. [CrossRef] [PubMed]

51. Yesilova, Z.; Yaman, H.; Oktenli, C.; Ozcan, A.; Uygur, A.; Cakir, E.; Sanisoglu, S.Y.; Erdil, A.; Ates, Y.; Aslan, M.; et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. *Am. J. Gastroenterol.* 2005, 100, 850–855. [CrossRef]

52. Ergün, Y.; Kurutas, E.B.; Özdíl, B.; Günesçar, R.; Ergün, Y. Nitric Oxide and Nitrotyrosine Levels in Relation with Oxidative Stress-Related Markers in Non-Alcoholic Fatty Liver Disease. *Turk. Klin. J. Gastroenterohepatol.* 2011, 18, 1–8.

53. Videla, L.A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quiñones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A.; et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. *Clin. Sci.* 2004, 106, 261–268. [CrossRef]

54. Kumar, A.; Sharma, A.; Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Kohli, K.K.; Bhansali, A. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. *J. Clin. Exp. Hepatol.* 2013, 3, 12–28. [CrossRef] [PubMed]

55. Sumida, Y.; Nakashima, T.; Yoh, T.; Furutani, M.; Hirohama, A.; Kakisaka, Y.; Nakajima, Y.; Ishikawa, H.; Mitsuyoshi, H.; Okanoue, T.; et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. *J. Hepatol.* 2003, 38, 32–38. [CrossRef]

56. Salomone, F.; Volti, G.L.; Rosso, C.; Grosso, G.; Bugianesi, E. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with nonalcoholic steatohepatitis and advanced fibrosis. *J. Gastroenterol. Hepatol.* 2013, 28, 1202–1208. [CrossRef] [PubMed]

57. Hjelkrem, M.; Morales, A.; Williams, C.D.; Harrison, S.A. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). *Aliment. Pharmacol. Ther.* 2012, 35, 1416–1423. [CrossRef] [PubMed]

58. Kumar, R.; Rastogi, A.; Maras, J.S.; Sarin, S.K. Unconjugated hyperbilirubinemia in patients with non-alcoholic fatty liver disease: A favorable endogenous response. *Clin. Biochem.* 2012, 45, 272–274. [CrossRef] [PubMed]

59. Horoz, M.; Bolukbas, C.; Bolukbas, F.F.; Sabuncu, T.; Aslan, M.; Sarfakıogulları, S.; Gunaydın, N.; Erel, O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. *BMC Gastroenterol.* 2005, 5, 35. [CrossRef] [PubMed]

60. Farhan, A.R. Evaluation of Melatonin Hormone and Nitric oxide Levels in Non-alcoholic Fatty Liver Patients in Relation to Obesity and Oxidative Stress. *J. Pharm. Sci. Res.* 2018, 10, 1167–1169.

61. Loguercio, C.; De Girolamo, V.; de Sio, I.; Tuccillo, C.; Ascione, A.; Baldi, F.; Budillon, G.; Cimino, L.; Di Carlo, A.; Di Marino, M.P.; et al. Non-alcoholic fatty liver disease in an area of southern Italy: Main clinical, histological, and pathophysiological aspects. *J. Hepatol.* 2001, 35, 568–574. [CrossRef]
62. Oliveira, C.P.; Faintuch, J.; Rascovski, A.; Furuya, C.K., Jr.; Bastos, M.S.; Matsuda, M.; Della Nina, B.I.; Yahnos, K.; Abdala, D.S.; Vezozzo, D.C.; et al. Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD)—Preliminary findings. *Obes. Surg.* 2005, 15, 502–505. [CrossRef]

63. Seki, S.; Kitada, T.; Yamada, T.; Sagakuchi, H.; Nakatani, K.; Wakasa, K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. *J. Hepatol.* 2002, 37, 56–62. [CrossRef]

64. Fujita, N.; Miyachi, H.; Tanaka, H.; Takeo, M.; Nakagawa, N.; Kobayashi, Y.; Iwasa, M.; Watanabe, S.; Takei, Y. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. *Cancer Epidemiol. Biomark. Prev.* 2009, 18, 424–432. [CrossRef] [PubMed]

65. Nobili, V.; Parola, M.; Alisi, A.; Marra, F.; Piemonte, F.; Mombello, C.; Sutti, S.; Povero, D.; Maina, V.; Novo, E.; et al. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. *Int. J. Mol. Med.* 2010, 26, 471–476. [CrossRef] [PubMed]

66. Chitiou, H.; Semela, D.; Ledermann, M.; Zimmermann, A.; Dufour, J.F. Expression and activity of the cytochrome P450 2E1 in patients with non-alcoholic steatosis and steatohepatitis. *Liver Int.* 2007, 27, 764–771. [CrossRef] [PubMed]

67. Yoshioka, S.; Hamada, A.; Jobu, K.; Yokota, J.; Onogawa, M.; Kyotani, S.; Miyamura, M.; Saibara, T.; Onishi, S.; Nishioka, Y. Effects of Eriobotrya japonica seed extract on oxidative stress in rats with non-alcoholic steatohepatitis. *J. Pharm. Pharmacol.* 2010, 62, 241–246. [CrossRef] [PubMed]

68. Marcolin, E.; Forgiarini, L.F.; Rodrigues, G.; Tieppo, J.; Borghetti, G.S.; Bassani, V.L.; Picada, J.N.; Marroni, N.P. Quercetin Decreases Liver Damage in Mice with Non-Alcoholic Steatohepatitis. *Basic Clin. Pharmacol. Toxicol.* 2013, 112, 385–391. [CrossRef] [PubMed]

69. Marcolin, E.; Forgiarini, L.F.; Tieppo, J.; Dias, A.S.; Freitas, L.A.R.; Marroni, N.P. Methione- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. *Arq. Gastroenterol.* 2011, 48, 72–79. [CrossRef] [PubMed]

70. Nan, Y.M.; Wu, W.J.; Fu, N.; Liang, B.L.; Wang, R.Q.; Li, L.X.; Zhao, S.X.; Zhao, J.M.; Yu, J. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. *Scand. J. Gastroenterol.* 2009, 44, 1121–1131. [CrossRef] [PubMed]

71. Nosrati, N.; Aghazadeh, S.; Yazdanparast, R. Effects of Teurcuim polium on Insulin Resistance in Nonalcoholic Steatohepatitis. *J. Acupunct. Meridian Stud.* 2010, 3, 104–110. [CrossRef]

72. Huang, F.; Wang, J.; Yu, F.; Tang, Y.; Ding, G.; Yang, Z.; Sun, Y. Protective Effect of Meretrix meretrix Oligopeptides on High-Fat-Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. *Mar. Drugs* 2018, 16, 39. [CrossRef] [PubMed]

73. Li, W.; Lu, Y. Hepatoprotective Effects of Sophoricoside against Fructose-Induced Liver Injury via Regulating Lipid Metabolism, Oxidation, and Inflammation in Mice. *J. Food Sci.* 2018, 83, 552–558. [CrossRef]

74. Song, L.; Qu, D.; Zhang, Q.; Jiang, J.; Zhou, H.; Jiang, R.; Li, Y.; Zhang, Y.; Yan, H. Phytosterol esters attenuate hepatic steatosis in rats with nonalcoholic fatty liver disease rats fed a high-fat diet. *Sci. Rep.* 2017, 7, 41604. [CrossRef] [PubMed]

75. Korish, A.A.; Afrafah, M.M. Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease. *BMC Complement. Altern. Med.* 2013, 13, 264–276. [CrossRef] [PubMed]

76. Elshazly, S.M. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. *Eur. J. Pharmacol.* 2015, 748, 123–132. [CrossRef] [PubMed]

77. Janevski, M.; Antonas, K.N.; Sullivan-Gunn, M.J.; McGlynn, M.A.; Lewandowski, P.A. The effect of cocoa supplementation on hepatic steatosis, reactive oxygen species and LFABP in a rat model of NASH. *Comp. Hepatol.* 2011, 10, 10. [CrossRef] [PubMed]

78. Caballero, F.; Fernández, A.; Matías, N.; Martínez, L.; Fucho, R.; Elena, M.; Caballería, J.; Morales, A.; Fernández-Clavell, J.C.; García-Ruiz, C. Specific Contribution of Methionine and Choline in Nutritional Nonalcoholic Steatohepatitis. *J. Biol. Chem.* 2010, 285, 18528–18536. [CrossRef] [PubMed]

79. Schröder, T.; Kucharzyn, D.; Bär, F.; Page, R.; Derer, S.; Jendrek, T.; Sünderrauf, A.; Brethack, A.K.; Hirose, M.; Möller, S.; et al. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. *Mol. Metab.* 2016, 5, 283–295. [CrossRef]

80. Sutti, S.; Jindal, A.; Locatelli, I.; Vacciano, M.; Gigliotti, L.; Bozzola, C.; Albano, E. Adaptive Immune Responses Triggered by Oxidative Stress Contribute to Hepatic Inflammation in NASH. *Hepatology* 2014, 59, 886–897. [CrossRef]
81. Nazmy, M.H.; Abdel-Ghany, M.I. Serum markers versus histopathological scoring for discrimination between experimental fatty liver and non-alcoholic steatohepatitis. *Int. Res. J. Med. Med. Sci.* 2015, 3, 51–59.

82. Sugatani, J.; Wada, T.; Osabe, M.; Yamakawa, K.; Yoshinari, K.; Miwa, M. Dietary Inulin Alleviates Hepatic Steatosis and Xenobiotics-Induced Liver Injury in Rats Fed a High-Fat and High-Sucrose Diet: Association with the Suppression of Hepatic Cytochrome P450 and Hepatocyte Nuclear Factor 4α Expression. *Drug Metab. Dispos.* 2006, 34, 1677–1687. [CrossRef]

83. Takahashi, Y.; Sugimoto, K.; Soejima, Y.; Kumagai, A.; Koeda, T.; Shojo, A.; Nakagawa, K.; Harada, N.; Yamaji, R.; Inui, H.; et al. Inhibitory Effects of Eucalyptus and Banaba Leaf Extracts on Nonalcoholic Steatohepatitis Induced by a High-Fructose/High-Glucose Diet in Rats. *Biomed. Res. Int.* 2015, 2015, 1–9. [CrossRef]

84. Watanabe, M.; Fuda, H.; Okabe, H.; Joko, S.; Miura, Y.; Hui, S.; Hamaoka, Y.N.; Miki, E.; Chiba, H. Oyster extracts attenuate pathological changes in non-alcoholic steatohepatitis (NASH) mouse model. *J. Funct. Foods* 2016, 20, 516–531. [CrossRef]

85. Ji, G.; Wang, Y.; Deng, Y.; Li, X.; Jiangm, Z. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline deficient diet-induced steatohepatitis through regulating autophagy. *Lipids Health Dis.* 2015, 14, 134. [CrossRef] [PubMed]

86. Sakaia, I.; Okita, K. The role of oxidative stress in NASH and fatty liver model. *Hepatol. Res.* 2005, 33, 128–131. [CrossRef] [PubMed]

87. Nakamoto, K.; Takayama, F.; Mankura, M.; Hidaka, Y.; Egashira, T.; Ogino, T.; Kawasaki, H.; Morim, A. Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis. *J. Clin. Biochem. Nutr.* 2009, 44, 239–246. [CrossRef] [PubMed]

88. Lieber, C.S.; Leo, M.A.; Mak, K.M.; Xu, Y.; Cao, Q.; Ren, C.; Ponomarenko, A.; DeCarli, L.M. Model of nonalcoholic steatohepatitis. *Am. J. Clin. Nutr.* 2004, 79, 502–509. [CrossRef] [PubMed]

89. Chung, Y.M.; Park, H.J.; Manautou, J.E.; Koo, S.I.; Bruno, R.S. Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. *J. Nutr. Biochem.* 2012, 23, 361–367. [CrossRef] [PubMed]

90. Verbeek, J.; Spincemaille, P.; Vanhorebeek, I.; Van den Berghe, G.; Vander Elst, I.; Windmolders, P.; van Pelt, J.; van der Merwe, S.; Bedossa, P.; Nevers, F.; et al. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. *Lipids Health Dis.* 2017, 23, 46–56. [CrossRef]

91. Lee, S.J.; Kang, J.H.; Iqbal, W.; Kwon, O.S. Proteomic Analysis of Mice Fed Methionine and Choline Deficient Diet Reveals Marker Proteins Associated with Steatohepatitis. *PloS ONE* 2015, 10, e0120577. [CrossRef]

92. Jung, Y.A.; Choi, Y.K.; Jung, G.S.; Seo, H.Y.; Kim, H.S.; Jang, B.K.; Kim, J.G.; Lee, I.K.; Kim, M.K.; Park, K.G. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. *Diabetes Res. Clin. Pract.* 2014, 105, 47–57. [CrossRef]

93. Kathirve, E.; Chen, P.; Morgan, K.; French, S.W.; Morgan, T.R. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. *J. Gastroenterol. Hepatol.* 2010, 25, 1136–1143. [CrossRef]

94. Lieber, C.S.; Leo, M.A.; Mak, K.M.; Xu, Y.; Cao, Q.; Ren, C.; Ponomarenko, A.; DeCarli, L.M. Acarbose attenuates experimental non-alcoholic steatohepatitis. *Biochem. Biophys. Res. Commun.* 2004, 12, 699–703. [CrossRef] [PubMed]

95. Wang, Y.; Ausman, L.M.; Greenberg, A.S.; Russell, R.M.; Wang, X. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. *Int. J. Cancer* 2010, 126, 1788–1796. [CrossRef] [PubMed]

96. Murakami, S.; Takayama, F.; Egashira, T.; Imao, M.; Mori, A. Fermented papaya preparation halts the progression of non-alcoholic steatohepatitis in rats. *J. Biophys. Chem.* 2013, 4, 84–90. [CrossRef]